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Abstract 
The purpose of this study was to compare the effect of resistance training (RT) 
duration, including years of exposure, on agonist and antagonist neuromuscular activation 
throughout the knee extension voluntary torque range. Fifty-seven healthy men (untrained 
[UNT] n=29, short-term RT [12WK] n=14, and long-term RT [4YR] n=14) performed 
maximum and sub-maximum (20-80% maximum voluntary torque [MVT]) unilateral 
isometric knee extension contractions with torque, agonist and antagonist surface EMG 
recorded. Agonist EMG, including at MVT, was corrected for the confounding effects of 
adiposity (i.e. muscle-electrode distance; measured with ultrasonography). Quadriceps 
maximum anatomical cross-sectional area (QACSAMAX; via MRI) was also assessed. MVT 
was distinct for all three groups (4YR +60/+39% vs. UNT/12WK; 12WK +15% vs. UNT; 
0.001<P≤0.021), and QACSAMAX was greater for 4YR (+50/+42% vs. UNT/12WK; [both] 
P<0.001). Agonist EMG at MVT was +44/+33% greater for 4YR/12WK ([both] P<0.001) vs. 
UNT; but did not differ between RT groups. The torque-agonist EMG relationship of 4YR 
displayed a right/down shift with lower agonist EMG at the highest common torque (196 
Nm) compared to 12WK and UNT (0.005≤P≤0.013; Effect size [ES] 0.90≤ES≤1.28). The 
torque-antagonist EMG relationship displayed a lower slope with increasing RT duration 
(4YR<12WK<UNT; 0.001<P≤0.094; 0.56≤ES≤1.31), and antagonist EMG at the highest 
common torque was also lower for 4YR than UNT (-69%; P<0.001; ES=1.18). In conclusion, 
4YR and 12WK had similar agonist activation at MVT and this adaptation may be 
maximised during early months of RT. In contrast, inter-muscular coordination, specifically 
antagonist co-activation was progressively lower, and likely continues to adapt, with 
prolonged RT. 
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Introduction 
Regular resistance training (RT) leads to increases in maximum strength, the 
maximum force/torque that can be produced by the trained musculature. These improvements 
in strength can increase the mobility of older adults 
1
, enhance athletic performance 
2
, reduce 
injury risk 
3
, and may decrease the likelihood of developing musculoskeletal disorders, such 
as osteoarthritis 
4
. Consequently, regular and persistent RT is recommended for athletes, the 
general population, and older adults alike 
5,6
. Neural adaptations have been widely 
documented to contribute to the increases in strength following short-term RT (up to 16 
weeks in duration; 
7-13
). It has often been assumed that changes in neuromuscular activation 
primarily occur in this initial short-term period of RT with no/minimal further adaptations 
thereafter 
14
, although there is evidence that extensive neuroplasticity can occur in response 
to long-term RT 
15-17
. At present, however it is unclear if adaptations in neuromuscular 
activation continue to occur with prolonged RT (i.e. over several years) and might contribute 
to changes in function (strength). 
 
Surface electromyography (EMG) measurements have generally demonstrated 
increased neuromuscular activation of the agonist muscles at maximum torque after relatively 
short-term RT 
8-13
, although whether these adaptations in maximum agonist activation 
continue over longer periods of RT remains largely unexplored. Two longitudinal RT 
interventions with already highly resistance-trained men found no
 18
 or marginal 
19
 
improvements in activation during isometric actions. Furthermore, Moritani and deVries 
20
 
first proposed that changes in the full range of the torque-agonist EMG relationship may 
reveal useful information regarding the nature of underpinning physiological adaptations 
following RT. They hypothesised that changes in the position and extension of the torque-
agonist EMG relationship after training could indicate neural (Fig. 1A), morphological (Fig. 
 4 
1B), or a combination of both neural and morphological adaptations (Fig. 1 C) 
20
. Existing 
literature suggests an extension of the torque-agonist EMG relationship following 4 wk of RT 
11,21
 (e.g. Fig. 1A, neural adaptation), but a shift to the right with no extension after 8 wk to 6 
mo of RT 
22-24
 (e.g. Fig. 1B, morphological, but no neural adaptation) which represents an 
incongruous time course of neural adaptations (increase and then decrease). Whilst it is likely 
the classic Moritani and DeVries model over simplifies the relative contribution of neural and 
morphological adaptations, the influence of more prolonged RT (i.e. for multiple years) on 
the torque-agonist EMG relationship has not been examined, and thus the time course of any 
changes remains unknown. In the first few months of RT the changes in strength appear to be 
primarily dependent on neural adaptations 
25
 and thus a similar, but extended, torque-agonist 
EMG relationship may be expected (Fig. 1A). Whereas with years of RT substantial 
hypertrophic, in addition to neural, adaptations are thought to occur 
26
 and the relationship 
may be expected to shift down/right, whilst extending to a similar maximum EMG as 
observed after short-term RT (Fig. 1C).  
 
Antagonist co-activation at maximum torque has been found to be unchanged 
27
, 
increased 
28
, and decreased 
29
 following short-term RT studies. These differences may be 
because antagonist co-activation is positively related to both torque and agonist activation, 
such that increased maximum torque and agonist activation after RT tend to cause an increase 
in antagonist co-activation, even if antagonist co-activation at the same torque has decreased 
11
. In which case the relationships between antagonist co-activation and torque/agonist 
activation may provide a more complete assessment. In fact, Tillin et al 
11
 found that after 
short-term RT co-activation was reduced at any absolute level of torque/agonist activation, 
even though co-activation at maximum torque was unchanged, likely due to the increase in 
torque/agonist activation. However, whether prolonged RT, leads to further potentially more 
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substantial adaptations in antagonist co-activation, beyond these short-term changes, is 
unclear. 
 
Overall, it is unknown whether several years of RT causes continued adaptations in 
agonist activation and antagonist co-activation, and specifically changes the nature of the 
inter-relationships between these neural variables and torque, beyond those documented by 
short-term intervention studies. Whilst a longitudinal study of several years duration may be 
impractical, a comparison of groups with distinct durations of RT experience may facilitate 
investigation of these issues. Therefore, the purpose of the current investigation was to 
conduct a detailed comparison between untrained (UNT) vs. short-term RT (12 weeks 
[12WK]) vs. long-term RT (average 4 years [4YR]) men for agonist and antagonist 
neuromuscular activation throughout the voluntary torque range. The position of the torque-
agonist EMG and torque-antagonist EMG relationships were assessed by determining their 
slope and also EMG amplitude at the highest common torque (i.e. the highest torque achieved 
by all participants). Based on limited existing evidence it was hypothesised that maximum 
agonist activation would be greater for 12WK vs. UNT, but with no further difference 
between 12WK and 4YR. It was also hypothesised that the torque-agonist EMG relationship, 
would: have a similar position, for 12WK vs. UNT (Fig. 1A); have a down/rightwards 
position for 4YR vs. UNT and 12WK (Fig. 1C). The final hypothesis was that antagonist co-
activation at the same torque/agonist activation would progressively decrease with greater 
training duration (i.e. lower position of the torque-antagonist EMG relationship; 
4YR<12WK<UNT). 
 
Materials and Methods 
Participants 
 6 
A total of fifty-seven young, healthy, asymptomatic, males provided written informed 
consent prior to participation in this study that was approved by the Loughborough 
University Ethical Advisory Committee. Physical activity levels of all participants were 
assessed with the International Physical Activity Questionnaire [IPAQ, short format 
30
]. The 
UNT group consisted of 29 participants (IPAQ: 2358 ± 1476 metabolic equivalent min/wk) 
who had not completed lower-body RT for >18 months and were not involved in systematic 
physical training. The 12WK group comprised 14 participants (IPAQ: 2097 ± 1303 metabolic 
equivalent min/wk) measured within a week of completing 12-weeks of supervised isometric 
knee extension RT (3 x/wk, 40 reps of 3 s at 75% maximum voluntary torque [MVT]), who 
were originally recruited from an identical population to the UNT group (i.e. no RT for >18 
months and not involved in any systematic physical training). Finally, the 4YR group 
consisted of 14 participants (IPAQ: 5568 ± 1457 metabolic equivalent min/wk) who reported 
(via a detailed questionnaire and follow-up oral discussion) systematic, progressive heavy RT 
of the quadriceps (i.e. completion of several knee extensor exercises within an individual 
session ~3 x/wk typically consisting of: squat, lunge, step-up, and leg press) for ≥3 years 
(mean ± SD, 4 ± 1 years; range, 3-5 years) with the primary aim of developing maximum 
strength. The RT of this group had not been experimentally supervised although some of 
these participants had received variable coaching (technique and programming) support. Use 
of androgenic-anabolic steroids was an exclusion criterion for all participants. Many 
individuals in the 4YR group reported regular use of nutritional supplements (e.g. whey 
protein and creatine). 
 
Overview 
UNT, 12WK, and 4YR participants visited the neuromuscular laboratory for a 
familiarisation session involving isometric voluntary maximum and sub-maximum 
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contractions. Thereafter, two duplicate neuromuscular measurement sessions were conducted 
on the dominant leg (7-10 days apart). Finally, MRI and ultrasound scans were performed 
within 7 days of the second neuromuscular measurement session. Neuromuscular 
measurement sessions were at a consistent time of day for each individual and started 
between 12:00-19:00. These sessions involved recordings of isometric knee extension/flexion 
torque and surface EMG of the superficial quadriceps and hamstrings muscles during 
voluntary maximum and a range of sub-maximum contractions (20, 40, 60 and 80%). The 
primary outcome measures were maximum torque and simultaneous agonist and antagonist 
EMG, as well as the position of the torque-agonist EMG and torque-antagonist EMG 
relationships assessed by both relationship slope and EMG at the highest common torque. 
Whilst not primary outcomes the following measurements were also completed: (i) muscle 
size, assessed with a T1-weighted 1.5T MRI scan of the thigh of each participant’s dominant 
leg (see “Muscle size” below), as an additional index of training status and morphological 
differences between the three groups; and (ii) muscle-electrode distance (MED) using B-
mode ultrasonography at the sites where quadriceps EMG sensors were placed to correct for 
the pronounced, confounding influence of subcutaneous tissue thickness, primarily body fat, 
on voluntary EMG amplitude 
31
. 
 
12WK supervised resistance training intervention 
All training sessions involved the same dynamometer and configuration used for the 
measurements (see below). After a brief warm-up of sub-maximum contractions of both legs, 
participants completed four sets of ten sustained unilateral isometric knee extension 
contractions of each leg; with sets alternating between dominant and non-dominant legs until 
4 sets per leg had been completed. Each set took 60 s with 2 min between successive sets on 
the same leg. This training model has been described extensively elsewhere 
8
 and was 
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selected for the 12WK group within the current study as it has shown to produce increases in 
maximum strength during short-term RT interventions 
11,32
. Briefly, participants were 
presented with a target torque trace (on a computer monitor in front of them) 2 s before every 
contraction and were instructed to match this target trace, which increased torque linearly 
from rest to 75%MVT over 1 s before holding a plateau at 75%MVT for a further 3 s. 12WK 
participants performed three maximum voluntary isometric contractions (MVCs; see below) 
at the start of each training week to re-establish MVT and prescribe training torques. 12WK 
participants were instructed to maintain their habitual physical activity and diet throughout 
the 12-week training period. 
 
Torque and EMG recording 
Measurements were completed in a rigid custom-made isometric dynamometer with 
knee and hip angles of 115° and 126° (180° = full extension), respectively (as shown in Fig. 
6B of reference 
33
). Adjustable straps were tightly fastened across the pelvis and shoulders to 
prevent extraneous movement. An ankle strap (35 mm width reinforced canvas webbing) was 
placed ~15% of tibial length (distance from lateral malleolus to knee joint space), above the 
medial malleolus, and positioned perpendicular to the tibia and in series with a calibrated S-
beam strain gauge (Force Logic, Swallowfield, UK). The analogue force signal from the 
strain gauge was amplified (x370) and sampled at 2,000 Hz using an external A/D converter 
(Micro 1401; CED Ltd., Cambridge, UK) and recorded with Spike 2 computer software 
(CED Ltd., Cambridge, UK). In offline analysis, force data were low-pass filtered at 500 Hz 
using a fourth-order zero-lag Butterworth filter, gravity corrected by subtracting baseline 
force, and multiplied by lever length, the distance from the knee joint space to the centre of 
the ankle strap, to calculate torque values. 
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Surface EMG was recorded from the superficial quadriceps (agonist EMG: rectus 
femoris [RF]; vastus lateralis [VL]; vastus medialis, [VM]) and hamstring muscles 
(antagonist EMG: biceps femoris [BF] and semitendinosus [ST]) using a wireless EMG 
system (Trigno; Delsys Inc., Boston, MA). Before single differential Trigno Standard EMG 
sensors (Delsys Inc., Boston, MA; fixed 1-cm interelectrode distance) were positioned skin 
preparation (shaving, abrading, and cleansing with 70% ethanol) was conducted. Individual 
sensors were attached (using adhesive interfaces) at six separate sites over the superficial 
quadriceps muscles at set percentages of thigh length (above the superior border of the 
patella) as follows: RF 65 and 55%; VL 60 and 55%; VM 35 and 30%. Similarly, individual 
sensors were placed on the BF and ST at 45% of thigh length above the popliteal fossa. 
Sensors were placed parallel to the presumed orientation of the underlying fibres. EMG 
signals were amplified at source (x300; 20- to 450-Hz bandwidth) before further 
amplification (overall effective gain, x909), and sampled at 2,000 Hz via the same A/D 
converter and computer software as the force signal, to enable data synchronization. In 
offline analysis, EMG signals were corrected for the 48-ms delay inherent to the Trigno EMG 
system. 
 
Measurement sessions 
Following a brief warm-up of the dominant leg (3 s knee extension contractions at 
50% [x3], 75% [x3], and 90% [x1] of perceived maximum) measurements were completed in 
the following order. 
 
Knee extension maximum voluntary contractions 
Participants performed 3-4 MVCs and were instructed to “push as hard as possible” 
for 3-5 s and rest for ≥30 s between efforts. A torque-time curve with a horizontal cursor 
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indicating the greatest torque obtained within that session was displayed for biofeedback and 
verbal encouragement was provided during all MVCs 
11,34
. Knee extensor MVT was the 
greatest instantaneous torque achieved during any MVC during that measurement session. 
Root mean square (RMS) EMG for a 500 ms epoch at MVT (250 ms either side) was 
calculated for each electrode site. RMS EMG from each quadriceps site was then averaged to 
provide an overall quadriceps EMG measurement during MVT production (agonist 
EMGMVT). RMS EMG from each of the hamstring sites during knee extension MVT 
(antagonist EMGMVT) was normalised to that measured during knee flexion MVT (knee 
flexion EMGMAX; see below) and then averaged across the two hamstring sites. 
 
Knee extension sub-maximum voluntary contractions 
Horizontal cursors indicating four sub-maximum target torque levels were placed on 
the screen displaying the real-time torque-time curve and participants were instructed to 
gradually increase torque (over ~1 s) and match the prescribed torque level for ~5 s at 20, 40, 
60 or 80%MVT, performed in this order, with ≥30 s between efforts. From each recorded 
contraction, a 500 ms period of stable torque at approximately the prescribed level was 
identified and used to calculate mean knee extension torque. RMS EMG of each quadriceps 
and hamstring EMG site was measured for each of these epochs. 
 
Knee flexion maximum voluntary contractions 
Knee flexion MVCs were performed in the same manner as knee extension, except 
participants performed a series of sub-maximum knee flexion efforts to warm-up and were 
instructed to “pull as hard as possible” for 3-5 s, rather than “push” 11,34. Knee flexion MVT 
was the greatest instantaneous torque achieved during any MVC during that measurement 
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session. RMS hamstring EMG for a 500 ms epoch at knee flexion MVT (250 ms either side) 
was analysed for each site (knee flexion EMGMAX). 
 
Muscle size 
A 1.5T MRI scan of the dominant leg was made in the supine position at a knee joint 
angle of ~163° using a receiver 8-channel whole body coil (Signa HDxt, GE). T1-weighted 
axial slices (5 mm thick, 0 mm gap) were acquired from the anterior superior iliac spine to 
the knee joint space in two overlapping blocks. Oil filled capsules placed on the lateral side 
of the participants’ thigh allowed alignment of the blocks during analysis. MR images were 
analysed by two trained investigators using Osirix software (version 6.0, Pixmeo, Geneva, 
Switzerland). The quadriceps (RF, VL, VM, and vastus intermedius; VI) muscles were 
manually outlined in every third image (i.e. every 15 mm) starting from the most proximal 
image in which the muscle appeared. The image with the largest anatomical cross-sectional 
area (ACSA) was defined as the maximum ACSA for each individual quadriceps muscle and 
the sum of the muscles was defined as maximum quadriceps ACSA (QACSAMAX). 
 
Muscle-electrode distance and correction of agonist EMG. 
 Images of the distance between the skin surface and the peripheral surface of the 
muscle at each of the six sites where quadriceps EMG sensors were positioned (i.e. muscle-
electrode distance, MED) were collected using a B-mode ultrasonography machine (EUB-
8500, Hitachi Medical Systems UK Ltd, Northamptonshire, UK) with a 9.2 cm wide linear-
array transducer (EUP-L53L), sampling at 32 Hz, interfaced with a personal computer 
operating ezcap video capture software. The transducer was coated with water-soluble 
transmission gel and placed perpendicular to the skin over the RF, VL, and VM at the 
percentages of thigh length listed above for each quadriceps EMG sensor. Images were later 
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imported in to a public domain software (Tracker version 4.92; 
www.cabrillo.edu/~dbrown/tracker) and MED was measured by one trained investigator. 
 
When agonist EMG data for all participants was pooled (i.e. n= 57) there were inverse 
relationships between absolute EMG amplitude and MED for all sensor locations and all 
types of contraction (maximum and all sub-maximum levels; Pearson’s product moment 
bivariate correlations, -0.670 ≤ r ≤ -0.394; 0.001<P≤0.002). Additionally, when comparing 
the three groups MED differed or tended to differ (One-way ANOVA 0.014≤P≤0.070) with 
several “Moderate” to “Large” effect sizes (0.71≤ES≤1.03) between groups at three out of six 
sites. Consequently, all individual agonist EMG measurements were corrected for MED at 
the corresponding site, using the quadratic relationship between agonist EMG amplitude and 
MED at that specific measurement site. Correcting EMG amplitude measurements for the 
amount of subcutaneous tissue at the recording site 
35
 or using MED as a covariate within 
statistical testing 
36
 are approaches that have previously been employed. The MED correction 
in the current study involved summating the individual’s residual absolute agonist EMG 
amplitude, in comparison to the cohort relationship with MED (e.g. agonist EMG amplitude 
vs. MED), with the pooled group mean for absolute agonist EMG amplitude 
37
. Overall 
corrected agonist EMG during all maximum and sub-maximum contractions was then 
calculated by averaging the corrected EMG amplitude measurements from each EMG 
recording site.  
 
Data analysis and statistics 
All torque and EMG measurements from the two neuromuscular measurement 
sessions were averaged to produce criterion values. Bivariate relationships were then 
analysed with Pearson’s product moment correlation. Only agonist EMG values corrected for 
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MED were used for establishing relationships. Three relationships were plotted and assessed 
for each individual participant: knee extension torque vs. corrected agonist EMG; knee 
extension torque vs. normalised antagonist EMG; and normalised antagonist EMG vs. 
corrected agonist EMG. Relationships were fitted with linear functions, but not forced 
through zero as forcing the function through zero significantly reduced the R
2
 values of all 
three relationships (paired t-test, [all] P<0.001). The position of the torque-agonist EMG and 
torque-antagonist EMG relationships were assessed with: (i) relationship slope (‘m’ constant 
of the linear function) and (ii) EMG at the highest common torque achieved by all 
participants (196 Nm, equivalent to the MVT of the weakest participant and indicated as a 
vertical dotted line in Fig. 3A and B). EMG values for each participant at the highest 
common torque were derived by solving the individual linear function (for an x axis value of 
196 Nm) for the relationship between isometric knee extension torque and either agonist or 
antagonist EMG. The slope of the antagonist EMG-agonist EMG relationship was also 
calculated. 
All statistical analyses were performed using SPSS Version 24.0 (IBM Corp., 
Armonk, NY). Data are reported or displayed as means ± SD, except in figures displaying 
EMG relationships where for presentation purposes data points with x and y error bars to the 
far right of the figure display average SD for the five load increments across the voluntary 
torque range for each group. One-way ANOVAs were conducted as the main statistical tests 
to assess if differences existed between groups for: descriptive characteristics (i.e. age, 
height, and body mass); agonist EMGMVT; antagonist EMGMVT; the slope derived from the 
relationships (i.e. torque-agonist EMG, torque-antagonist EMG, antagonist EMG-agonist 
EMG); and agonist EMG and antagonist EMG at the highest common knee extension torque. 
When one-way ANOVAs displayed P<0.05, a combined post-hoc criteria involving both a 
least significant difference (LSD) P value of <0.10 and an effect size (ES) >0.50 were 
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required for there to be considered good evidence of between-group differences. LSD P 
values were stepwise corrected for multiple comparisons 
38
 and ES was calculated as 
previously detailed for between-subject study designs 
39
 and classified as follows: <0.20 
“Trivial,” 0.20 – 0.49 “Small,” 0.50 – 0.80 “Moderate,” or >0.80 “Large”. 
 Between-test session reliability of key measurements was assessed by pooling all 
three groups of participants (i.e. n= 57) using: (i) within-participant coefficient of variation 
(CVW, [SD/mean] × 100) as a measure of absolute reliability; and (ii) intra-class correlation 
coefficient (ICC; two-way mixed, absolute agreement) to assess relative reliability. CVW 
values were interpreted as “acceptable” <12%, “intermediate” 12–20%, or “unacceptable” 
>20% 
40
. ICC values were interpreted as ‘‘very high’’ 0.90–1.00, ‘‘high’’ 0.70–0.89, 
“moderate” 0.50–0.69, “low” 0.30–0.49, “negligible” 0.00–0.29 41. 
 
Results 
Between-test session reliability 
 Knee extension and knee flexion MVT returned mean CVW values of 2.7% and 
10.8% and ICC values of 0.980 and 0.889, respectively. Absolute agonist and antagonist 
EMG at knee extension MVT demonstrated mean CVW values of 8.8% and 17.8% and ICC 
values of 0.937 and 0.774, respectively. Agonist EMG corrected for MED and normalised 
antagonist EMG (both) at knee extension MVT produced mean CVW values of 8.3% and 
25.8% and ICC values of 0.876 and 0.790, respectively. 
 
Descriptive characteristics, muscle strength and size 
Age, height, and body mass were similar for 12WK (24 ± 2 y; 1.75 ± 0.08 m; 70 ± 9 
kg) and UNT (25 ± 2 y; 1.76 ± 0.07 m; 74 ± 10 kg) groups ([all variables] LSD P≥0.247). 
The 4YR group were younger (22 ± 2 y), taller (1.84 ± 0.06 m), and heavier (92 ± 10 kg) than 
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the other two groups ([all variables] LSD P≤0.004). Knee extension MVT of 12WK (293 ± 
49 Nm) was 15% greater than UNT (255 ± 42 Nm; LSD P=0.021; ES=0.86 “Large”), whilst 
MVT of 4YR (407 ± 63 Nm) was 60% greater than UNT and 39% greater than 12WK ([both] 
P<0.001; 2.02≤ES≤3.07 [both] “Large”; Fig. 2A). Knee flexion MVT of 4YR (104 ± 21 Nm) 
was 72% greater than UNT (61 ± 23 Nm; LSD P<0.001; ES=1.91 “Large”) and 63% greater 
than 12WK (64 ± 15 Nm; P<0.001; ES=2.19 “Large”), but no differences in knee flexion 
MVT occurred between 12WK and UNT (P=0.636; ES=0.16 “Trivial”). QACSAMAX of 4YR 
was 50% greater than UNT and 42% greater than 12WK ([both] LSD P<0.001; 
2.78≤ES≤3.63 [both] “Large”); but did not differ between 12WK and UNT (P=0.204; 
ES=0.42 “Small”; Fig. 2B). 
 
Absolute agonist and antagonist EMG at knee extension maximum voluntary torque 
Absolute agonist EMGMVT was greater for 4YR (+66%; LSD P<0.001; ES= 1.53 
“Large”) and 12WK (+32%; P=0.050; ES=0.78 “Moderate”) compared to UNT (Table 1). In 
addition, absolute agonist EMGMVT was greater for 4YR than 12WK (+25%; LSD P=0.048; 
ES=0.72 “Moderate”; Table 1). In contrast, there were no statistical differences between 
groups for absolute antagonist EMGMVT (Table 1). 
 
Corrected agonist and normalised antagonist EMG at knee extension maximum voluntary 
torque 
 Agonist EMGMVT (corrected for MED) was greater for both 4YR (+44%; LSD 
P<0.001; ES=1.73 “Large”) and 12WK (+33%; P<0.001; ES=1.29 “Large”) than UNT; but 
was not statistically different between the two RT groups (P=0.281; ES=0.35 “Small”; Fig. 
2C and Table 1). Normalised antagonist EMG at knee extension MVT was not different 
between groups (Table 1).  
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Knee extension torque-agonist EMG relationship 
The torque-agonist EMG relationship was well represented by a linear function with 
high R
2
 values for all three groups regardless of RT experience (4YR, 0.978 ± 0.026; 12WK, 
0.970 ± 0.054; UNT, 0.972 ± 0.066). There were no differences between the groups for slope 
of the torque-agonist EMG relationship (Table 1; Fig. 3A). However, agonist EMG at the 
highest common torque (196 Nm) was lower for 4YR compared to UNT (-24%; LSD 
P=0.013; ES=0.90 “Large”) and 12WK (-30%; P=0.005; ES=1.28 “Large”) indicating a 
downward shift in the torque-agonist EMG relationship (Fig. 4A). No differences in agonist 
EMG at 196 Nm occurred between 12WK and UNT (LSD P=0.296; ES=0.35 “Small”; Fig. 
4A). 
 
Knee extension torque-antagonist EMG relationship  
The torque-antagonist EMG relationship was well represented by a linear function 
with high R
2
 values regardless of RT experience (4YR, 0.971 ± 0.020; 12WK, 0.952 ± 0.043; 
UNT, 0.894 ± 0.111). The slope of the knee extension torque-antagonist EMG relationship 
differed between all three groups (Table 1), being lower for 12WK than UNT (-30%; LSD 
P=0.061; ES=0.56 “Moderate”), and lower for 4YR than 12WK (-52%; P=0.094; ES=1.22 
“Large”) or UNT (-66%; P<0.001; ES=1.31 “Large”; Fig. 3B and Table 1). Antagonist EMG 
at 196 Nm of knee extension torque was lower for 4YR compared to UNT (-69%; LSD 
P<0.001; ES=1.18 “Large”; Fig. 4B and Table 1) but not vs. 12WK (P=0.108; ES=1.23 
“Large”). No differences in antagonist EMG at 196 Nm occurred for 12WK compared to 
UNT (LSD P=0.120; ES=0.46 “Small”; Fig. 4B). 
 
Antagonist EMG-Agonist EMG relationship during knee extension contractions 
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The slope of the antagonist EMG-agonist EMG relationship was lower for both 4YR 
(-59%; LSD P<0.001; ES=1.22 “Large”) and 12WK (-37%; P=0.028; ES=0.77 “Moderate”) 
vs. UNT (Fig. 5 and Table 1). The 12WK group appeared to occupy an intermediate position 
between the other two groups although there was no difference between the slopes of the two 
trained groups (12WK vs. 4YR; LSD P=0.202; ES=0.69 “Moderate”; Fig. 5). High R2 values 
for the antagonist EMG-agonist EMG relationship were displayed for all groups regardless of 
RT experience (4YR, 0.982 ± 0.012; 12WK, 0.972 ± 0.031; UNT, 0.892 ± 0.135). 
 
 
Discussion 
 The purpose of this study was to compare neuromuscular activation of the agonist and 
antagonist musculature during knee extension contractions throughout the voluntary torque 
range between long-term RT (4YR), short-term RT (12WK) and untrained (UNT) groups. In 
agreement with our hypothesis, maximum agonist activation (corrected for MED) was higher 
for both RT groups than UNT, but did not differ between 12WK and 4YR. As hypothesised, 
the torque-agonist EMG relationship for 12WK had a similar position to UNT (slope and 
agonist EMG at 196 Nm), for 4YR occupied a lower position than the other two groups 
(lower agonist EMG at 196 Nm), although the slope was similar for all groups. The position 
of the torque-antagonist EMG relationship also showed distinct differences between groups 
with lower slope according to RT duration (4YR<12WK<UNT) and lower antagonist EMG 
at the highest common knee extension torque for 4YR vs. UNT. Based on these findings it 
appears that changes in maximum agonist activation predominantly occur in the first weeks 
of RT, but not substantially thereafter, although the 4YR RT group displayed a 
down/rightwards position of the torque-agonist EMG relationship presumably due to 
substantial hypertrophy. In contrast, the lower antagonist co-activation for 4YR than 12WK, 
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evidenced by differences in the slope of the torque-antagonist EMG relationship, suggests 
that inter-muscular co-ordination may be the primary long-term neural adaptation to RT. 
 
 The greater agonist activation (both absolute EMG and corrected for MED) at 
maximum voluntary torque of both RT groups compared to the untrained cohort supports 
numerous previous reports that agonist activation increases following RT 
8-13
, although some 
older studies have reported no change in agonist EMG amplitude after RT 
22,23
. Moreover, the 
greater neuromuscular activation (maximum agonist EMG) of 12WK vs. UNT, coupled with 
the similar muscle size of these groups supports the concept that strength gains following 
short-term RT result predominantly from neural adaptations 
14,20
. In fact, we recently found 
the largest determinant of the change in strength following 12-weeks of RT to be the increase 
in agonist neuromuscular activation (EMG), explaining 30.6% of the variance in strength 
gains 
25
. The greater agonist neuromuscular activation of 12WK vs. UNT may be due to 
increased motor unit firing rate 
42
 and/or recruitment of additional motor units 
43
, but these 
mechanisms were not discernible from the current EMG amplitude measurements. Whilst 
absolute agonist EMG also showed differences between the two RT groups (12WK vs. 4YR) 
this appeared to be in part due to the lower MED of the 4YR group, as there were no 
differences in agonist EMG amplitude between the two RT cohorts, once corrected for MED. 
Overall, these findings suggest that maximum agonist activation increases in the first 12 
weeks of RT, but does not continue to adapt beyond 12 weeks of RT (up to ~4 years). 
 
The consistent position, but extended, torque-agonist EMG relationship of 12WK 
compared to UNT in the current cross-sectional study was in agreement with short-term 
longitudinal RT studies 
11,21
. The lower agonist EMG at the highest common torque of the 
4YR group (vs. UNT or 12WK) confirmed the visual impression that the torque-agonist 
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EMG relationship was positioned further to the right for this group, despite the observation 
that the slope of the torque-agonist EMG relationship was similar for all three groups. The 
longest intervention studies we are aware of reported a qualitative reduction in the slope of 
the torque-agonist EMG relationship after 6 months of RT 
23,24
, which is broadly supportive 
of the observation that the position of the relationship is adaptable and shifts down/right with 
prolonged RT. A logical explanation of the 4YR group’s lower agonist EMG amplitude to 
produce the same knee extension torque, and thus the subsequent down/rightwards position 
of the torque-agonist EMG relationship of this group, is substantial hypertrophy 
20
 and/or 
possible greater neuromuscular efficiency 
44
. Indeed, the 4YR group had considerably larger 
quadriceps than the other two groups (+42/+50% greater QACSAMAX vs. 12WK/UNT). 
Hypertrophied muscle would be expected to require activation of fewer, but larger, fibres to 
achieve the same torque production and hence lower agonist EMG. 
 
Antagonist EMG amplitude at knee extension MVT was not different between 
groups, despite 4YR having 28-38% lower normalised antagonist EMG than the other 
groups. Measurements of antagonist EMG amplitude at MVT are likely confounded by the 
differences in MVT between groups, which demonstrably effects antagonist EMG via the 
extremely strong torque-antagonist EMG relationship we have described (R
2
>0.89), as well 
as the large variability in this measurement 
11
, and these issues probably explain the confused 
findings for antagonist co-activation at MVT within the literature 
27-29
. In this case the 
position of the relationships between antagonist EMG and torque/agonist EMG or antagonist 
EMG at a common torque level may be a more reliable and meaningful measures of 
antagonist co-activation. In fact, the slope of the torque-antagonist EMG relationship was 
distinct between all three groups (4YR<12WK<UNT), being ~two-thirds less steep for 4YR 
than UNT. Similarly, antagonist EMG at the highest common knee extension torque was also 
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substantially lower for 4YR than UNT (-69%), and even though not significantly different 
comparably large differences were demonstrated between 4YR vs 12WK (-57%). Finally, the 
agonist-antagonist activation relationship appeared visually to show distinct and 
progressively lower positions according to RT duration, but only revealed differences for 
both RT groups vs. UNT. Overall, these findings provide convincing evidence that antagonist 
co-activation shows substantial scope for continued adaptation beyond the first 12 weeks of 
training, and thus may be the primary long-term neural adaptation to RT. 
 
The finding that antagonist co-activation was progressively lower as a function of RT 
duration (i.e. slope of torque-antagonist EMG relationship: UNT>12WK>4YR), despite there 
being no difference in maximum agonist activation between groups with 12 weeks or ~4 
years of RT experience, indirectly supports cortical excitability and spinal reflex response 
research suggesting that agonist and antagonist activation are modulated by different 
supraspinal mechanisms 
45
. Whilst our understanding of the precise mechanisms (i.e. 
supraspinal and/or spinal) that modulate antagonist co-activation is still incomplete 
46
, the 
progressive decrease in antagonist co-activation across the three groups with increasing RT 
experience in the current study indicates that with prolonged RT (up to ~4 years) antagonist 
co-activation likely contributes to increased strength due to reduced antagonist knee flexion 
torque. It would be highly interesting to be able to accurately translate these apparent changes 
in antagonist neuromuscular activation to quantitative changes in antagonist torque, however 
this is problematic for several reasons: we have assessed co-activation of only two of nine 
knee flexor muscles; such a calculation would require the agonist EMG-knee flexion torque 
relationship of all these muscles; which is itself confounded by antagonist quadriceps 
activation. Nonetheless, on a relatively simplistic level, assuming a linear knee flexion 
torque-agonist EMG relationship in order to calculate antagonist knee flexion torque (i.e. % 
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normalised antagonist EMG x knee flexion MVT) at the common knee extensor torque of 
196 Nm, reveals antagonist torque for UNT of 11.6 Nm (19.0% x 61 Nm), 8.8 Nm for 12WK 
(13.7% x 64 Nm) and 6.1 Nm for 4YR (5.9% x 104 Nm). The observation that maximum 
agonist neuromuscular activation was similar for 12WK compared to 4YR, whilst antagonist 
co-activation showed some marked but functionally small differences between these groups, 
strongly supports the notion that other adaptations, primarily morphological changes, such as 
the 4YR group’s substantial hypertrophy (QACSAMAX: +42% vs. 12WK), is the primary 
explanation for their much greater strength (MVT: +114 Nm vs. 12WK). 
 
Given the practical issues with implementing supervised RT interventions for 
multiple years the results of the current study provide novel insight in to how the human 
neuromuscular system likely adapts with continued RT. Nonetheless it is important to 
consider the limitations of the current study. The cross-sectional design clearly provides a 
weaker level of evidence than longitudinal intervention studies, and make it impossible to 
fully discern the contribution of selection (i.e. innate differences [nature]), as opposed to the 
influence of RT (nurture), which is the primary question of this research. For example, it is 
conceivable that individuals attracted to regular prolonged RT (i.e. the 4YR group), are 
innately stronger, perhaps due to specific neuromuscular differences conceivably including 
better inter-muscular co-ordination, than the normal population. Nonetheless, whilst the 4YR 
group were clearly selected for their characteristic RT history, and thus were by definition 
distinct from the normal population, this was not the case for the 12WK group that were 
initially recruited from an identical population as the UNT group with only a minor 
proportion randomly assigned to the 12WK RT intervention. Thus, within the current 
findings when there is a clear progression across the groups (i.e. UNT>12WK>4YR as for 
the slope of the torque-antagonist EMG relationship) we can be more confident that this was 
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not due to selection bias, but in all probability due to the duration of RT. In addition, when 
there are no differences between groups (e.g. 4YR vs. 12WK as for corrected agonist EMG 
during MVT) it seems likely that RT duration does not have a pronounced effect. 
 
Although both the 12WK and 4YR groups were performing heavy RT, the contraction 
modes employed were different between the two groups (i.e. 12WK: isometric RT; 4YR: 
concentric and eccentric RT). It is possible that the task specific training of the 12WK group 
(isometric training specific to isometric testing) might have produced task-specific neural 
adaptations 
8,47
, which was not the case for the 4YR group, and thus accentuated task-specific 
adaptations of 12WK may have minimised the neural differences between these two groups. 
In this case the neural, and potentially also strength, differences that we have documented 
between 12WK and 4YR may well have been more pronounced given identical RT modes. 
Nonetheless the pronounced differences in strength between these groups appeared to be 
primarily due to morphological differences, rather than similar corrected agonist activation or 
functionally small differences in antagonist co-activation between the groups. Moreover, 
multiple-year longitudinal RT intervention studies employing contemporary EMG 
techniques, careful antagonist EMG-torque/agonist EMG relationships, and measurements at 
multiple intervals throughout the course of the intervention are required to confirm the 
findings we report here. Whilst we considered including the interpolated twitch technique in 
the current study, it was excluded due to several studies demonstrating its limited sensitivity 
to detect changes in activation after RT 
11,48-50
. 
 
It should also be noted that the results of the present investigation could be specific to 
the knee joint and the open kinetic chain knee extension task that was used. Further thorough 
investigations of agonist, antagonist, and stabiliser muscle activation during other single-joint 
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and also multiple-joint and/or multiplanar strength tasks are necessary to gain greater 
understanding of the nature of neural adaptations to long-term RT. The limitations of surface 
EMG measurements have been widely documented and may not provide an ideal index of the 
neural drive to the muscle 
51
. For example, the size of the surface action potential has been 
found to be only moderately associated with motor unit size 
52
. In addition, it is possible that 
amplitude cancellation (i.e. when positive and negative phases of concurrent action potentials 
overlap and reduce the sum of the surface EMG measurement) could have influenced the 
results of the current study 
53
, especially given there is evidence that increased motor unit 
synchronisation can occur following RT 
15,54
. Therefore, it is recommended that future work 
utilise other techniques (e.g. EMG decomposition, transcranial magnetic stimulation) to 
better understand the changes in muscle activation with prolonged RT. 
 
In conclusion, it appears that maximum agonist activation changes predominantly 
occur in the first weeks of RT (up to 12 wk), but not substantially thereafter, although long-
term RT (up to ~4 years) led to a rightwards shift of the torque-agonist EMG relationship 
presumably due to the substantial hypertrophy of these participants. Interestingly, antagonist 
co-activation was progressively lower according to RT duration suggesting that inter-
muscular co-ordination may be the primary long-term neural adaptation to RT. Multiple-year 
longitudinal RT intervention studies employing appropriate neural measurements at multiple 
intervals throughout the course of the intervention are required to confirm the cross-sectional 
findings observed in the present investigation. 
 
Perspectives 
 Prior to this study it was largely unexplored whether several years of resistance 
training (RT) causes continued adaptations in agonist activation and antagonist co-activation 
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beyond short-term RT, although Moritani & DeVries (1979) hypothesised specific changes in 
the torque-agonist EMG relationship according to neural (short-term) and hypertrophic (long-
term) adaptations. Differences in agonist activation were broadly as speculated by Moritani & 
DeVries (1979) with greater maximum agonist activation after short-term, but without further 
changes after long-term RT, and a rightwards shift in the torque-agonist activation 
relationship only after long-term RT. In addition, it was particularly interesting that there was 
lower co-activation of the antagonist muscles according to RT duration that suggests 
continued improvements in inter-muscular co-ordination. The findings of the current 
investigation have potential implications for the practices and physiological understanding of 
individuals prescribing and/or undertaking long-term RT. Future research in this area is 
clearly warranted to investigate the influence of long-term (multiple-year) RT interventions 
on agonist, antagonist, and stabiliser neuromuscular activation during diverse mechanical 
tasks/conditions (including isometric and isoinertial, and single- and multiple-joint and/or 
multiplanar strength tasks). 
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FIGURE CAPTIONS 
 
Fig. 1 Illustration of pre- to post-training changes in the torque-agonist EMG relationship 
considered to be representative of: (A) exclusively neural adaptations (unchanged slope but 
extended relationship with a right and upward shift of the maximum point; (B) exclusively 
hypertrophic adaptations (lower slope with the maximum point shifted to the right); (C) a 
combination of neural and hypertrophic adaptations (lower slope, but with a maximum point 
shifted to the right and upwards). Adapted from Moritani and deVries 
20
. 
 
Fig. 2 (A) Knee extension maximum voluntary torque; (B) quadriceps maximum anatomical 
cross-sectional area (QACSAMAX); and (C) agonist EMG amplitude (corrected for muscle-
electrode distance) of untrained (UNT), short-term resistance-trained (12WK), and long-term 
resistance-trained (4YR) groups. Data are mean ± SD. Symbols indicate differences between 
groups: * greater than UNT; † greater than 12WK. 
 
Fig. 3 The relationship between torque and (A) agonist EMG amplitude (corrected for 
muscle-electrode distance) and (B) normalised antagonist EMG throughout the knee 
extension voluntary torque range for untrained (UNT), short-term resistance-trained (12WK), 
and long-term resistance-trained (4YR) groups. Data points to the far right of Fig. 3A and B 
display x and y error bars that are the mean SD for torque (x error bars) and EMG amplitude 
(y error bars) for the five load increments across the voluntary torque range for each group. 
Knee Flexion EMGMAX, agonist EMG during isometric knee flexion maximum voluntary 
torque. 
 
Fig. 4 (A) Agonist EMG amplitude (corrected for muscle-electrode distance); and (B) 
normalised antagonist EMG at the highest common isometric knee extension torque achieved 
by all participants (196 Nm; derived by solving individual linear equations) for untrained 
(UNT), short-term resistance-trained (12WK), and long-term resistance-trained (4YR) 
groups. Data are mean ± SD. Symbols indicate differences between groups: * lower than 
UNT; † lower than 12WK. Knee Flexion EMGMAX, agonist EMG during isometric knee 
flexion maximum voluntary torque. 
 
Fig. 5 The relationship between agonist EMG amplitude (corrected for muscle-electrode 
distance) and normalised antagonist EMG throughout the knee extension voluntary torque 
range for untrained (UNT), short-term resistance-trained (12WK), and long-term resistance-
trained (4YR) groups. Data points to the far right of the figure display x and y error bars that 
are the mean SD for agonist EMG (x error bars) and antagonist EMG (y error bars) amplitude 
for the five load increments across the voluntary torque range for each group. Knee Flexion 
EMGMAX, agonist EMG during isometric knee flexion maximum voluntary torque. 
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TABLES 
 
Table 1. Agonist and antagonist surface EMG amplitudes and the slope of the relationship between agonist EMG and torque/antagonist EMG for untrained 
(UNT), short-term resistance-trained (12WK), and long-term resistance-trained (4YR) groups. 
 
  UNT (n=29) 12WK (n=14) 4YR (n=14) ANOVA P value 
    
 
    
Activation at MVT:   
 
    
Absolute agonist EMG (mV) 0.182 ± 0.073 0.241 ± 0.081* 0.301 ± 0.087*† <0.001 
Absolute antagonist EMG (mV) 0.019 ± 0.009 0.020 ± 0.007 0.016 ± 0.008 0.540 
    
 
    
Corrected agonist EMG (mV) 0.192 ± 0.042 0.255 ± 0.061* 0.277 ± 0.060* <0.001 
Normalised antagonist EMG (% Knee flexion EMGMAX) 23.1 ± 14.0 20.0 ± 10.0 14.4 ± 10.9 0.107 
    
 
    
Activation at highest common torque (196 Nm) 
 
    
Corrected agonist EMG (mV) 0.151 ± 0.039 0.164 ± 0.039 0.116 ± 0.040*† 0.004 
Normalised EMG (% Knee flexion EMGMAX) 19.0 ± 13.2 13.7 ± 7.8 5.9 ± 4.5* 0.001 
    
 
    
Slope of linear relationship:   
 
    
Torque (Nm)-Corrected agonist EMG (mV) 8.163 ± 2.186 x 10
-4
 9.280 ± 2.578 x 10
-4
 7.507 ± 2.461 x 10
-4
 0.138 
Torque (Nm)-Normalised antagonist EMG (% Knee flexion EMGMAX) 0.109 ± 0.065 0.077 ± 0.041* 0.037 ± 0.023*† <0.001 
Normalised antagonist EMG (% Knee flexion EMGMAX)-Corrected agonist EMG (mV) 132 ± 72 83 ± 41* 54 ± 43* <0.001 
 
Data are mean ± SD. One-way ANOVAs and subsequent post-hoc tests were used to establish differences between groups. Symbols indicate differences between groups: * Different than 
UNT; † Different than 12WK. Knee flexion EMGMAX, agonist EMG during isometric knee flexion maximum voluntary torque. Corrected agonist EMG was calculated by using the quadratic 
relationship between EMG amplitude and muscle-electrode distance for all participants (n=57) on a sensor and contraction intensity specific basis before averaging across sites to derive overall 
agonist EMG measurements. 
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